Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Monday, 12'th May 2025
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:21am, Thursday, 08'th May 2025
Beyond analysts' top -and-bottom-line estimates for Exelixis (EXEL), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarte
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
04:05pm, Wednesday, 07'th May 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
10:55am, Friday, 02'nd May 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
04:05pm, Tuesday, 29'th Apr 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00
MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points
08:00am, Saturday, 26'th Apr 2025
Stocks near buy points include Charles Schwab, German software leader SAP and MercadoLibre, the so-called Amazon of Latin America,
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
02:30pm, Friday, 25'th Apr 2025
Investors will likely focus on the demand for Cabometyx and pipeline updates when EXEL reports Q1 results.
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:40am, Thursday, 24'th Apr 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release
11:06am, Tuesday, 22'nd Apr 2025
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
10:50am, Wednesday, 16'th Apr 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
01:16pm, Friday, 11'th Apr 2025
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:46am, Tuesday, 08'th Apr 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Smartest Biotech Stocks to Buy With $50
06:15am, Thursday, 03'rd Apr 2025
One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that perform well tend to attract plenty of attention that bids up their share pri
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
04:00pm, Thursday, 27'th Mar 2025
Exelixis obtains FDA nod for label expansion of lead drug Cabometyx for neuroendocrine tumors.
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?
04:01pm, Wednesday, 26'th Mar 2025
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value. However, the recent rally might limit further gains for shareholders.
